Inhaled Therapy of Respiratory Infections
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 84
Special Issue Editors
Interests: pulmonary drug delivery; dry powder formulation; micromeritics; nano formulation
Special Issue Information
Dear Colleagues,
Respiratory infections remain a major global health challenge, often requiring high systemic drug doses that lead to toxicity and limited therapeutic efficacy. Inhaled therapy offers a direct and efficient route to deliver medications to the lungs, enabling high local concentrations while minimizing systemic exposure. Recent advances in aerosol technology, formulation engineering, and respiratory support systems have significantly expanded the therapeutic potential for treating viral, bacterial, and fungal infections.
This Special Issue aims to explore recent progress and emerging strategies in inhaled therapies for respiratory infections, as well as supportive inhaled approaches for respiratory infection management. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: inhaled therapies for respiratory infections, aerosol delivery performance, pulmonary PK/PD studies, targeted inhalation strategies, and treatment responses in infected patients.
We look forward to receiving your contributions.
Dr. Wei-Ren Ke
Prof. Dr. Hui-Ling Lin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inhaled drug delivery
- respiratory infections
- anti-infective aerosols
- pulmonary pharmacokinetics
- targeted lung delivery
- clinical translation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
